Table 1. Patient demographics and pre-operative clinical characteristics (n=33).
| Variable | Value |
|---|---|
| Age at implant (year) | 68 [65–72] |
| Male sex | 31 (94%) |
| Ischemic HF etiology | 17 (51%) |
| BMI (kg/m2) | 26.02±5.85 |
| INTERMACS profile (*) | |
| 1 | 4 (12%) |
| 2 | 3 (9%) |
| 3 | 18 (55%) |
| 4 | 8 (24%) |
| NYHA functional class | |
| I | 0 |
| II | 0 |
| III | 17 (52%) |
| IV | 16 (48%) |
| Intention to treat | |
| DT | 30 (91%) |
| BTT/BTC | 3 (9%) |
| Diabetes | 10 (30%) |
| Creatinine (mg/dL) | 1.48 (1.16–1.80) |
| Hemoglobin (g/dL) | 11.5 (10.3–12.2) |
| Temporary MCS | 30 (91%) |
| HVAD | 15 (45%) |
| HM3 | 18 (55%) |
*, INTERMACS with TCS-modifier. HF, heart failure; BMI, body mass index; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; NYHA, New York Heart Association; DT, destination therapy; BTT, bridge to transplant; BTC, bridge to candidacy; MCS, mechanical circulatory support (Intra Aortic Balloon Pump, Impella, Extra-Corporeal Membrane Oxygenation); HVAD, HeartWare Ventricular Assist Device; HM3, HeartMate3 Ventricular Assist Device.